Royalty Pharma plc RPRX
NASDAQ
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 2.37% | 6.91% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.37% | 6.91% | |||
| Cost of Revenue | -132.93% | 235.82% | |||
| Gross Profit | 91.77% | -50.98% | |||
| SG&A Expenses | -11.94% | 12.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -76.17% | 28,500.10% | |||
| Operating Income | 321.58% | -78.95% | |||
| Income Before Tax | 227.22% | -82.60% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 227.22% | -82.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -91.76% | 63.36% | |||
| Net Income | 709.01% | -93.93% | |||
| EBIT | 321.58% | -78.95% | |||
| EBITDA | 318.43% | -78.79% | |||
| EPS Basic | 706.97% | -94.04% | |||
| Normalized Basic EPS | 627.28% | -118.66% | |||
| EPS Diluted | 709.50% | -94.06% | |||
| Normalized Diluted EPS | 628.43% | -119.01% | |||
| Average Basic Shares Outstanding | 0.22% | 1.89% | |||
| Average Diluted Shares Outstanding | 0.02% | 0.01% | |||
| Dividend Per Share | 0.00% | 0.00% | |||
| Payout Ratio | -0.88% | 15.55% | |||